{"nctId":"NCT01366638","briefTitle":"A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection","startDateStruct":{"date":"2011-05"},"conditions":["Hepatitis C, Chronic"],"count":79,"armGroups":[{"label":"Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48","type":"EXPERIMENTAL","interventionNames":["Drug: TMC435","Drug: Peginterferon alfa-2b (pegIFN alfa-2b)","Drug: Ribavirin (RBV)"]},{"label":"Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48","type":"EXPERIMENTAL","interventionNames":["Drug: TMC435","Drug: Peginterferon alfa-2b (pegIFN alfa-2b)","Drug: Ribavirin (RBV)"]},{"label":"Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48","type":"EXPERIMENTAL","interventionNames":["Drug: TMC435","Drug: Peginterferon alfa-2b (pegIFN alfa-2b)","Drug: Ribavirin (RBV)"]}],"interventions":[{"name":"TMC435","otherNames":[]},{"name":"Peginterferon alfa-2b (pegIFN alfa-2b)","otherNames":["PEGINTRON"]},{"name":"Ribavirin (RBV)","otherNames":["REBETOL"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient must have chronic genotype 1 HCV infection with HCV RNA level \\>= 5.0 log10 IU/mL\n* Patient has never received treatment for HCV (treatment-naive), relapsed after previous IFN-based therapy (prior relapser) or failed to respond to previous IFN-based therapy (non-responder)\n* Patient must be willing to use contraceptive measures from the time of informed consent to 6 months after last dose of study medication.\n\nExclusion Criteria:\n\n* Co-infection with any other HCV genotype or co-infection with the human immunodeficiency virus (HIV)\n* Diagnosed with hepatic cirrhosis or hepatic failure\n* A medical condition which is a contraindication to peg-IFN or ribavirin therapy\n* History of, or any current medical condition, which could impact the safety of the patient in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)","description":"The table below shows the percentage of participants in each treatment group with an SVR12 defined as participants with undetectable plasma Hepatitis C virus (HCV) ribonucleic acid (RNA) at the end of treatment (Week 24 or 48) who also had undetectable plasma HCV RNA 12 weeks after the last dose of treatment (Week 36 or 60). NOTE: All outcome measures reported in this study are \"Exploratory;\" not \"Primary\" as indicated (refer to Limits and Caveats).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"38.5","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)","description":"The table below shows the percentage of participants in each treatment group with a SVR24 defined as participants with undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) at the end of treatment and at 24 weeks after the last dose of treatment (Week 48 or 72). NOTE: All outcome measures reported in this study are \"Exploratory;\" not \"Primary\" as indicated (refer to Limits and Caveats).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"38.5","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment","description":"The table below shows the percentage of participants in each treatment group with undetectable HCV RNA less than 1.2 log10 IU/mL during treatment and at end of treatment (EOT). NOTE: All outcome measures reported in this study are \"Exploratory;\" not \"Primary\" as indicated (refer to Limits and Caveats).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.2","spread":null},{"groupId":"OG001","value":"86.2","spread":null},{"groupId":"OG002","value":"57.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"65.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"57.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"57.7","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Participants With Viral Breakthrough","description":"The table below shows the number of participants in each treatment group who experienced viral breakthrough during the TMC435 treatment period. Viral breakthrough is defined as a confirmed increase of greater than 1 log10 IU/mL in plasma hepatitis C virus (HCV) ribonucleic acid (RNA) level from the lowest level reached or a confirmed value of plasma HCV RNA of greater than 2.0 log10 IU/mL in participants whose plasma HCV RNA level had previously been reported below 1.2 log10 IU/mL detectable or undetectable. NOTE: All outcome measures reported in this study are \"Exploratory;\" not \"Primary\" as indicated (refer to Limits and Caveats).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Participants Demonstrating Viral Relapse","description":"The table below shows the number of participants in each treatment group who demonstrated viral relapse, defined as having undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels at end of treatment (EOT \\[Week 24 or 48\\]) and detectable HCV RNA during follow-up or detectable HCV RNA at the time points of an assessment of sustained virologic response (SVR). The number of participants analyzed in each treatment group below are those with undetectable HCV RNA levels at EOT and with at least one follow-up HCV RNA measurement. NOTE: All outcome measures reported in this study are \"Exploratory;\" not \"Primary\" as indicated (refer to Limits and Caveats).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at the End of Treatment (EOT)","description":"The table below shows the number of participants in each treatment group with abnormal ALT levels at Baseline who achieved normalization of ALT levels defined as having an ALT value less than or equal to the Upper Limit of Normality (ie, 40 IU/mL) at EOT. At Baseline, 15 treatment-na√Øve participants, 13 prior relapsers, and 13 prior non-responders had abnormal ALT levels at Baseline. NOTE: All outcome measures reported in this study are \"Exploratory;\" not \"Primary\" as indicated (refer to Limits and Caveats).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up","description":"The table below shows the percentage of participants in each treatment group with greater than or equal to 2 log10 IU/mL drop from baseline in plasma hepatitis C virus (HCV) ribonucleic acid (RNA) at each time point during treatment and post-treatment follow-up. NOTE: All outcome measures reported in this study are \"Exploratory;\" not \"Primary\" as indicated (refer to Limits and Caveats).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"88.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"96.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"96.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"84.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"73.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"69.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"65.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"61.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"42.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"80.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"46.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"42.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"38.5","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2b (PegIFNŒ±-2b) and Ribavirin (RBV) at Week 24","description":"The table below shows the percentage of participants in each treatment group who met RGT criteria (ie, who had plasma levels of hepatitis C virus ribonucleic acid \\[HCV RNA\\] \\<1.2 log10 IU/mL detectable/undetectable at Week 4 and \\<1.2 log 10 IU/mL undetectable at Week 12) and completed treatment with PegIFNŒ±-2b and RBV at Week 24. Participants in the TMC435 Treatment-Na√Øve and TMC435 Prior Relapser treatment groups not meeting RGT criteria continued treatment with PegIFNŒ±-2a and RBV to Week 48 (does not apply to the TMC435 Non-responder treatment group because the specified treatment duration was 48 weeks and RGT criteria was not assessed at Week 24). NOTE: All outcome measures reported in this study are \"Exploratory;\" not \"Primary\" as indicated (refer to Limits and Caveats).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]}]},{"type":"PRIMARY","title":"The Area Under the Plasma Concentration-Time Curve (From 0 to 24 Hours) (AUC24h)","description":"The table below shows the median (range) AUC24h values for TMC435 for all participants in each TMC435 treatment group who received TMC435 for up to 12 weeks. \"Overall\" is the median exposure estimate using all available data for each participant in the study. NOTE: All outcome measures reported in this study are \"Exploratory;\" not \"Primary\" as indicated (refer to Limits and Caveats).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35448","spread":null},{"groupId":"OG001","value":"68130","spread":null},{"groupId":"OG002","value":"40645","spread":null}]}]}]},{"type":"PRIMARY","title":"Plasma Concentrations of TMC435","description":"The table below shows the median (range) TMC435 predose plasma concentrations (C0h) and maximum concentration (Cmax) values for participants in each treatment group. \"Overall\" is the median exposure estimate using all available data for each participant in the study. NOTE: All outcome measures reported in this study are \"Exploratory;\" not \"Primary\" as indicated (refer to Limits and Caveats).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2304","spread":null},{"groupId":"OG001","value":"3643","spread":null},{"groupId":"OG002","value":"2521","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"735","spread":null},{"groupId":"OG001","value":"2015","spread":null},{"groupId":"OG002","value":"921","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":24},"commonTop":["Pyrexia","White blood cell count decreased","Anaemia","Malaise","Headache"]}}}